跳至主要内容

Sweet Inflammatory Relief from a Familiar Tree

  Inflammation is a normal and expected physiological response to tissue trauma or infection. However, for a large portion of the population, these responses occur on a far more extensive and disruptive scale. Now that medical practitioners generally better understand the signs and symptoms of widespread and chronic inflammatory disorders—from obvious disorders such as rheumatoid arthritis and psoriasis to the lesser-understood connections between inflammation and diabetes, heart disease, and even cancer—the degree and occurrence of such cases represents a public health problem on a larger scale than imagined. As such, the push to discover simple but effective treatment methods is stronger than ever.



At present, as the pathogenesis of inflammatory and immunological diseases is unclear, there are few effective therapeutic drugs available in clinical practice. In such a context, the appropriate preclinical research techniques and models are required to help companies and researchers further develop and evaluate new drugs. Our Preclinical Pharmacodynamics Department has been deeply involved in this field for years, developing reliable animal-based efficacy evaluation models aimed at different targets and pathways, thus facilitating the clinical transformation of new drugs.

 

    Modern Western steroidal and nonsteroidal treatments lack the efficiency needed to make them effective in manageable doses, and larger doses have shown to cause too many adverse reactions to make them viable as long-term options. As it happens, several natural remedies, with a few synthesized twists, have shown a great deal of treatment potential, leading to the emergence of a class of biomolecular and phytochemical agents, including isoprenoids, phenolic compounds, and the increasingly popular flavonoids.


 

    A team of researchers from Quebec’s Université Laval—Sébastien Cardinal, Jabrane Azelmat, Daniel Grenier, and Normand Voyer—has turned its attention to these centuries-old plant-based treatments to see if these natural remedies can produce reliable and repeatable results. The team isolated a compound found in maple syrup, called quebecol, and found that, in in vitro bioassays, it has demonstrated strong potential as a chemopreventative and chemotherapeutic agent.

 

    To test the idea, molecules of quebecol were split into sub-molecules, designated North and South. These reduced and isolated molecule combinations were tested in a series of experiments involving additional benzyl groups and tetrasubstituted alkenes to target individual compounds. The quebecol and its derivatives were tested for anti-inflammatory activity using leukocytes, human macrophages that are essential immune system elements and whose usefulness in chronic inflammatory pathologies has been well-established. The leukocytes’ interleukin secretions, either amplified or reduced at various stages of the inflammatory process and thereby producing an accurate measure of inflammatory response, can establish therapeutic efficacy in treatments for both acute and chronic inflammatory disorders as well as some autoimmune diseases.

 

    The team’s results showed that the maple-derived quebecol compound does indeed produce an anti-inflammatory response in trials by inhibiting the leukocyte secretion of certain cytokines, specifically interleukin-6 and TNF-α, a compound that is crucial in the regulation of inflammatory responses and related disorders. The results also identified a relationship between structure and activity, most importantly the response and activity observed in quebecol1, a molecule derived from the North substructure.

 

    The ease of synthesizing this kind of compound may hold the key to developing a whole new class of effective plant-based anti-inflammatory compounds. The team is now working on preparing and developing such compounds, as well as ascertaining the potential in multiple quebecol analogs.

评论

此博客中的热门博文

What is preclinical testing?

In the process of  preclinical testing  of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a  preclinical research  phase followed, before which, as described above, the potential toxicity of the compou

Inventory of the three major in vitro pharmacokinetic research methods

  The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d

Novel Parkinson’s Therapies Possible with New Mouse Model

Parkinson's disease (PD) is a neurodegenerative disorder that is marked by the accumulation of the protein, α-synuclein (αS), into clumps known as Lewy bodies, which diminish neural health. Now, researchers from Brigham and Women's Hospital (BWH) report the development of a mouse model to induce PD-like αS aggregation, leading to resting tremor and abnormal movement control. The mouse responds to L-DOPA, similarly to patients with PD. The team's study (“Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson’s Disease”) on the use of this transgenic mouse model appears in  Neuron . “α-Synuclein (αS) regulates vesicle exocytosis but forms insoluble deposits in PD. Developing disease-modifying therapies requires animal models that reproduce cardinal features of PD. We recently described a previously unrecognized physiological form of αS, α-helical tetramers, and showed that familial PD-causing missense mutati